Prospective insights on the use of bTMB

Affiliations

Comment

David Killock. Nat Rev Clin Oncol. 2022 Jun.

. 2022 Jun;19(6):360.

doi: 10.1038/s41571-022-00640-2.

No abstract available

Comment on

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.
Kim ES, Velcheti V, Mekhail T, Yun C, Shagan SM, Hu S, Chae YK, Leal TA, Dowell JE, Tsai ML, Dakhil CSR, Stella P, Jin Y, Shames DS, Schleifman E, Fabrizio DA, Phan S, Socinski MA. Kim ES, et al. Nat Med. 2022 May;28(5):939-945. doi: 10.1038/s41591-022-01754-x. Epub 2022 Apr 14. Nat Med. 2022. PMID: 35422531 Free PMC article. Clinical Trial.

1. Kim, E. S. et al. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. Nat. Med. https://doi.org/10.1038/s41591-022-01754-x (2022) - DOI - PubMed - PMC